Advertisement
AMRX vs TEVA
Which Stock Would AI Choose? Amneal Pharmaceuticals (AMRX) vs. Teva Pharmaceutical Industries (TEVA) Stock Comparison
Key Takeaways
- Both AMRX and TEVA are prominent players in the generic pharmaceuticals sector, navigating pricing pressures and regulatory challenges.
- TEVA holds a much larger market capitalization of about $35.7 billion compared to AMRX's roughly $4 billion.
- TEVA shows stronger year-to-date (YTD) gains at 1.83% versus AMRX's 0.63%.
- Recent momentum favors TEVA, with shares up approximately 4% over the past 30 days amid a 118% one-year surge.
- AMRX benefits from solid preliminary Q1 results and a strategic acquisition, supporting steady performance around $12.50.
- Valuation contrast: TEVA's price-to-earnings (PE) ratio stands at 25.32, lower than AMRX's 56.91.
Introduction
This stock comparison pits AMRX, a U.S.-based generics specialist, against TEVA, the global generics leader with innovative biopharma ambitions. Both companies operate in the competitive healthcare sector, focusing on affordable essential medicines amid patent expirations and biosimilar opportunities. Traders seeking relative performance in generics may find value here, while long-term investors can assess growth drivers like branded expansions and acquisition strategies. Recent market activity highlights shifting sentiment influenced by earnings previews and strategic moves, offering insights into sector resilience and positioning.
AMRX Overview and Recent Performance
Amneal Pharmaceuticals, Inc. (AMRX), headquartered in Bridgewater, New Jersey, is a fully integrated essential medicines company specializing in generics, specialty pharmaceuticals, and biosciences. It develops, manufactures, and markets a broad portfolio targeting complex generics and high-barrier products. In recent market activity, AMRX shares have traded steadily around $12.50, reflecting resilience despite sector headwinds. Positive sentiment stems from solid preliminary first-quarter 2026 results and the announced buyout of Kashiv BioSciences, bolstering its pipeline. Year-to-date gains of 0.63% underscore modest momentum, supported by growth outlook for 2026 amid specialty segment expansion.
TEVA Overview and Recent Performance
Teva Pharmaceutical Industries Limited (TEVA) is the world's largest generic drug manufacturer, producing billions of tablets annually while advancing innovative biopharmaceuticals. Based in Israel with global operations, it emphasizes generics alongside higher-margin branded products and biosimilars. Over recent weeks, TEVA shares have climbed about 4% in the past 30 days, building on a remarkable 118% one-year surge to around $30.64. Key influences include focus on branded growth like AUSTEDO, projected to hit $2.5 billion in sales by 2027, analyst price target hikes to $42, and anticipation for Q1 2026 earnings. YTD performance at 1.83% signals sustained positive momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies, from short-term AI/ML signals (e.g., 5-60 minute timeframes) to longer holds, with impressive stats like annualized returns ranging from 93% to 167%, win rates of 48% to 88%, and profit factors up to 6.94. Examples include a semiconductors bot on SOXL yielding +93.61% annualized with 68% win rate, and a high-flyer on energy tickers at +167.52%. Tailored for current conditions, they offer real-time signals and risk management. Explore these for potential edges in volatile markets.
Head-to-Head Comparison
AMRX and TEVA share a generics-heavy business model but differ in scale: TEVA's global footprint dwarfs AMRX's U.S.-centric operations. Growth drivers contrast with TEVA leveraging branded catalysts like AUSTEDO and biosimilars for margin expansion, while AMRX emphasizes complex generics and acquisitions for pipeline depth. Recent momentum tilts to TEVA's upward trend versus AMRX's stability. Risk factors include generic pricing erosion and regulatory hurdles for both, though TEVA's debt profile adds leverage risk. Sector exposure is identical in healthcare generics, but market sentiment favors TEVA's transformation narrative amid analyst upgrades, positioning it for relative outperformance in choppy conditions.
Tickeron AI Verdict
Tickeron’s AI models would currently lean toward TEVA over AMRX, citing superior trend consistency, larger scale for stability, and catalysts like branded growth and upcoming earnings. TEVA's lower PE valuation and recent price gains suggest stronger relative positioning, though AMRX's acquisition momentum offers niche appeal. This probabilistic edge reflects observable technicals and fundamentals, not guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and TEVA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRX’s FA Score shows that 1 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).
- AMRX’s FA Score: 1 green, 4 red.
- TEVA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRX’s TA Score shows that 6 TA indicator(s) are bullish while TEVA’s TA Score has 3 bullish TA indicator(s).
- AMRX’s TA Score: 6 bullish, 4 bearish.
- TEVA’s TA Score: 3 bullish, 7 bearish.
Price Growth
AMRX (@Pharmaceuticals: Generic) experienced а -0.80% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was -8.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.31%. For the same industry, the average monthly price growth was +30.32%, and the average quarterly price growth was +14.63%.
Reported Earning Dates
AMRX is expected to report earnings on Aug 12, 2026.
TEVA is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.31% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| AMRX | TEVA | AMRX / TEVA | |
| Capitalization | 5.17B | 37.5B | 14% |
| EBITDA | 626M | 3.27B | 19% |
| Gain YTD | 28.651 | 0.865 | 3,312% |
| P/E Ratio | 43.81 | 23.49 | 186% |
| Revenue | 3.05B | 17.3B | 18% |
| Total Cash | 198M | 3.74B | 5% |
| Total Debt | 2.7B | 16.9B | 16% |
AMRX | TEVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 20 | 22 | |
SMR RATING 1..100 | 99 | 44 | |
PRICE GROWTH RATING 1..100 | 37 | 47 | |
P/E GROWTH RATING 1..100 | 100 | 89 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TEVA's Valuation (69) in the Pharmaceuticals Generic industry is in the same range as AMRX (85) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Profit vs Risk Rating (20) in the Pharmaceuticals Major industry is in the same range as TEVA (22) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's SMR Rating (44) in the Pharmaceuticals Generic industry is somewhat better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew somewhat faster than AMRX’s over the last 12 months.
AMRX's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as TEVA (47) in the Pharmaceuticals Generic industry. This means that AMRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's P/E Growth Rating (89) in the Pharmaceuticals Generic industry is in the same range as AMRX (100) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew similarly to AMRX’s over the last 12 months.
| AMRX | TEVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 4 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 86% | 4 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 67% |
| Advances ODDS (%) | 4 days ago 82% | 8 days ago 73% |
| Declines ODDS (%) | 18 days ago 70% | 2 days ago 68% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 58% |
Advertisement
AMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with AMPH. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To AMRX | 1D Price Change % | ||
|---|---|---|---|---|
| AMRX | 100% | -0.43% | ||
| AMPH - AMRX | 49% Loosely correlated | -3.09% | ||
| TEVA - AMRX | 45% Loosely correlated | -3.32% | ||
| VTRS - AMRX | 45% Loosely correlated | -2.29% | ||
| COLL - AMRX | 40% Loosely correlated | -0.42% | ||
| ANIP - AMRX | 36% Loosely correlated | -1.28% | ||
More | ||||
TEVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | -3.32% | ||
| AMRX - TEVA | 45% Loosely correlated | -0.43% | ||
| NBIX - TEVA | 42% Loosely correlated | -0.45% | ||
| VTRS - TEVA | 36% Loosely correlated | -2.29% | ||
| COLL - TEVA | 32% Poorly correlated | -0.42% | ||
| KMDA - TEVA | 30% Poorly correlated | +0.69% | ||
More | ||||